

FLORIDA MEDICAID

Prior Authorization

VFEND® (Voriconazole)

(Maximum of 90 Days Approval)

Note: Form must be completed in full. An incomplete form may be returned.

_																														
Re	cipie	ent's	Medi	caid	ID#	1	I	I		7		Dat	te of	Bi	rth	(MM	I/DD	/YYY ,	Y)	T		1	7							
Ļ	ecipient's Full Name																													
Re	СІРІЄ	ent's	Full I	Name)									Ŧ						1										
Pre	scri	iber's	Full	Nam	ie																									
Pre	scri	iber's	NPI	1	1		1	1	1	1										ı			•			ı				
Pre	rescriber Phone Number											Prescriber Fax Num										ıber								
			-				-															-				-				
	Vfe	nd® (vorico	nazo	ole)		_										50	mg ta	ab					40 m	g/ml	susp.		•		
	Vfend [®] (voriconazole) Initiation of therapy Continuation of therapy									200 mg tab						[als (I\										
	`	JUITUI	iualic	11 01	шіста	РУ																				lbs				kgs
	Directions										Quantity/30 Days							Weight												
1.	Ple	ease	che	ck a	ll tha	t ap	ply:	(Vfe	end	not	FD	4 <i>ap</i>	pro	ve	d fo	r pi	ropl	hylad	tic t	ther	apy)	١.								
		Cai Cai Dis	asive ndide ndidia semi ious	mia asis nate	in no of the d car	on-ne e esc ndidi	eutro opha asis	peni gus of th	c pa ne sk	itien kin a	its ind i	nfec	tion	s ir	th	e ab	odon	nen,	kidn	ey,										
2.	На	s pa	tient	rec	eive	d tra	nsp	lant?	?	□ '	Yes					No														
	Type:																			D	ate:									
3.	WI	hat a	ntifu	nga	l age	ent(s) ha	s the	e pat	tien	t re	ceiv	ed i	n t	he	pas	t 90	day	s?					_	_					
	Drug Name:																	Dates of Use:												
		F	Reas	on fo	or Dis	scont	tinuii	ng:																						
	Drug Name:										Dates of U										:									
		_	Reas		or Dis	scont	tinuii	ng:																						
4.	Sit	te(s)																												
5.		agno																				est	resi	ılts)						
٠.		•	telia		`					•		c Cl				•		e(s)			Bio			,						
6.	Vf	end _I										ologi			\Box			ogist,		\Box			us D	isea	se S	pecia	alist			
					_																									
		iber's RED F	_																								- t con	ioe o	f rolat	ha
		e pro														aiud	LIOI1	a a i i u	. 5081	in CI	art II	J.(63)	, and	uie i	11031	60611	ι συμ	163 0	ı ı c ıal	.c u

Mail or Fax Information to:

Prime Therapeutics State Government Solutions LLC Prior Authorization
P. O. Box 7082
Tallahassee, FL 32314-7082
Phone: 977 552 7494

Phone: 877-553-7481 Fax: 877-614-1078 Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.



FLORIDA MEDICAID PROTOCOL VFEND® (Voriconazole)

Approved Indications:

Invasive Aspergillosis:

- a. The "Invasive Aspergillosis" diagnosis must be checked.
- b. **Initial treatment** will be approved for **1 month** in patients suspected of having a life-threatening invasive Aspergillus infection that meet the following criteria:
 - Have a diagnosis indicating they are immunocompromised or are currently receiving immunosuppressive drugs; AND
 - Patient has clinical manifestations (symptoms, signs, and radiological features) compatible with the diagnosis of invasive aspergillosis. (**Supporting documentation must accompany request.**)
- c. The **remaining 60 days of therapy** may be granted upon receipt of a positive **Platelia Aspergillus EIA test** (detects circulating galactomannam antigen), biopsy or culture. A copy of the original lab results is required.
- d. New test results must accompany request for continuation of therapy after initial 90 days of therapy.

Treatment Failures:

Patient must have documented treatment failure with one or more of the following (except in the case of invasive aspergillosis):

- Amphotericin B (Abelcet[®], Fungizone[®])
- Flucanozole (Diflucan®)
- Ketoconazole (Nizoral[®])

Indication	PDL Alternatives (Current December 2007)								
Invasive Aspergillosis	Abelcet, amphotericin B, Fungizone								
Candidemia in non-neutropenic patients	Abelcet, amphotericin B, fluconazole, Fungizone								
Candidiasis of the Esophagus	Abelcet, amphotericin B, fluconazole, Fungizone, ketoconazole								
Disseminated candidiasis of the skin, and infections in the bladder wall, abdomen, kidney, and wounds	Abelcet, amphotericin B, fluconazole, Fungizone								
Scedosporium apiospermum and Fusarium species including Fusarium solani	Abelcet, amphotericin B, Fungizone								